浆膜腔积液中游离DNA靶向深度测序在恶性、可疑及良性细胞学中的应用
所有恶性(13/13)和可疑恶性(2/2)积液均检出致病性变异,1例良性积液(1/6)也检出。与11例配对FFPE样本比较,8例结果一致,3例上清检出额外耐药相关变异。
要点
- 浆膜腔积液上清cfDNA可成功进行靶向NGS,中位深度>1000×。
- 所有恶性及可疑恶性积液均检出致病性变异。
- 上清cfDNA可检出FFPE未发现的耐药相关变异。
核心结论
- 浆膜腔积液上清cfDNA是靶向NGS基因组分析的有前景来源。
研究设计与样本
- 与11例配对FFPE样本的检测结果进行比较验证。
主要发现
- 上清cfDNA中位浓度为10.3 ng/µL,所有积液均测序成功,中位深度>1000×。
- 检出单核苷酸变异、小插入缺失、扩增和融合等广泛遗传变异。
- 所有恶性积液(13/13)和可疑恶性积液(2/2)均检出致病性变异。
- 1例来自转移性癌症患者的良性积液(1/6)检出致病性变异。
- 11例配对FFPE比较中,8例结果一致,3例上清检出额外耐药相关变异。
关键数值与推荐
- FFPE与上清在DNA浓度(P = .5)、覆盖深度(P = .6)及致病突变等位基因频率(P = .7)上无差异。
临床怎么用
- 浆膜腔积液上清cfDNA可用于实体瘤靶向NGS基因分型。
- 对FFPE检测阴性或需耐药监测者,可考虑上清cfDNA补充检测。
局限性
- 1例良性积液检出致病性变异,提示需结合临床判读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liquid biopsy using cell-free DNA (cfDNA) presents new opportunities for solid tumor genotyping. While studies have demonstrated the utility of cfDNA from plasma, cfDNA from other body fluids remains underexplored. METHODS: We evaluated the molecular features and clinicopathologic correlates of cfDNA from serous body cavity fluids by performing hybrid capture-based next-generation sequencing (NGS) on cfDNA isolated from residual effusion supernatants. Twenty-one serous effusions from pleural (n = 15), peritoneal (n = 5), and pericardial (n = 1) cavity were analyzed. RESULTS: The supernatants provided a median cfDNA concentration of 10.3 ng/µL. Notably, all effusions were sequenced successfully to a median depth >1000×, revealing a broad range of genetic alterations including single nucleotide variants, small insertions and deletions, amplifications, and fusions. Specifically, pathogenic alterations were identified in all malignant fluids (13/13), all fluids suspicious for malignancy (2/2), and 1 benign fluid (1/6) from a patient with metastatic cancer. To validate our findings, we examined matching results from 11 patients who underwent additional testing using formalin-fixed, paraffin-embedded (FFPE) specimens. In 8 patients, the paired results between FFPE and supernatant testing were concordant, whereas in the remaining 3 patients, supernatant analysis identified additional variants likely associated with resistance to targeted therapies. Additional comparison between FFPE and supernatant testing showed no difference in DNA concentration (P = .5), depth of coverage (P = .6), or allele frequency of pathogenic mutations (P = .7). CONCLUSION: cfDNA isolated from serous body cavity fluids represents a promising source of genomic input for targeted NGS.
引用
- Yang SR, Mooney KL, Libiran P, et al. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology. Cancer Cytopathol. 2019. PMID: 31751001. doi:10.1002/cncy.22205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。